53 of the 68 men based on the TB of the lesion (82.5%), 38 patients upgraded by the 12-core TRUS biopsy (60.3%). There were 27 patients upgraded on both the targeted lesion biopsy and the 12-core biopsy. On sub analysis 22 men had a PI-RADS 5 lesion(s). CDR was 21/22 patients (95.5%). The PI-RADS 5 lesions had an upgrade cancer detection rate of 90.5% (19/21 patients with cancer detected. 43 men had a PI-RADS 4 lesion(s), CDR was 33/43 patients (76.7%). PI-RADS 4 lesions had an upgrade cancer detection rate of 81.8% (27/33 patients with cancer detected). The 12-core systemic biopsy had a false negative rate of 39.3%. The biopsies of MRI targeted lesions of interest in total had a false negative rate of 17.5% compared to 9.5% false negative rate of PI-RADS 5 targeted lesions and 18.2% false negative rate of PI-RADS 4 targeted lesions.
INTRODUCTION AND OBJECTIVES:
To evaluate the evidence of ultrasound-MRI fusion target biopsy on PI-RADS score 3 prostate lesions METHODS: Between October, 2016 and July, 2018, 151 patients underwent ultrasound guided systemic prostate biopsy (12 cores) and ultrasound-MRI fusion target biopsy (2 to 8 cores) concurrently. PI-RADS scores were estimated by 2 experienced uroradiologists. Patients were categorized by PI-RADS scores into 4 groups: PI-RADS score 1-2, 3, 4 and 5. We analyzed the differences of prostate cancer detection rates among 4 groups.
RESULTS: Age, prostate volume and number of target biopsy cores showed no significant differences among 4 groups. In PI-RADS score 3 group, mean positive core numbers and rate of positive cores were lower than systemic biopsy of total cohort ( p [ 0.02, 0.02, respectively) . Overall cancer and clinically significant cancer detection rates of target biopsy in PI-RADS score 3 group (15.8 %, 14.0 %, respectively) were lower than systemic biopsy (43.7 %; p < 0.01, 35.1 %; p < 0.01, respectively). Overall cancer and clinically significant cancer detection rates of target biopsy on PI-RADS score 3 lesions were similar with PI-RADS score 1-2 lesions, but lower than PI-RADS score 5 lesions (74.3 %; p < 0.01, 71.4 %; p < 0.01, respectively).
CONCLUSIONS: Ultrasound-MRI fusion target biopsies on PI-RADS score 3 prostate lesions showed lower overall cancer and clinically significant cancer detection rates than systemic biopsy. There is a lack of evidence to support target biopsies on PI-RADS score 3 prostate lesions. A prospective randomized study with large sample size is needed. We retrospectively reviewed 127 patients who underwent multiparametric magnetic resonance imaging (mpMRI) and RCP for bladder cancer between November 2016 and January 2018. Incidence of PCa was identified and clinicopathologic characteristics were compared according to the presence of incidental PCa. Clinically significant PCa (CSC) was defined as Gleason score ! 7 and/or pathologic tumor stage ! pT3. All mpMRI findings were assessed with PI-RADSv2 RESULTS: Of the 127 patients, median prostate specific antigen (PSA) was 1.38ng/ml and PI-RADSv2 score 4-5 was detected in 34 (26.8%) patients. Incidental PCa was identified in 28 (22.0%) patients, of which 12 (42.9%) patients showed CSC. When patients were divided according to incidental PCa, PSA and PI-RADSv2 score were not significantly different (P [ 0.014 and P [ 0.226, respectively). However, PSA was not different but PI-RADASv2 score 4-5 was more frequently identified in patients with CSC (80.0% [8/10] vs 12.5% [2/16], P [ 0.005). In 13 patients with PSA ! 2.5ng/ml and PI-RADSv2 score 4-5, incidental PCa was diagnosed with 5 (38.5%) patients, of which CSC was detected in 4 (80.0%) patients.
CONCLUSIONS: After RCP, incidental PCa was found in 22% of patients. PI-RADSv2 score 4-5 was significantly associated with CSC. PI-RADSv2 might be used as a preoperative imaging tool to determine risk classification and to help counsel patients with regard to treatment decision INTRODUCTION AND OBJECTIVES: Greater than 90% of TRUS-guided prostate biopsy cores are histopathologically classified as benign. Optical spectroscopy allows characterization of tumors by measurement of spectral tissue properties. As tissue undergoes malignant growth, the optical properties change. Assessment of changes in tissue optical properties may permit the diagnosis of prostate cancer (PCa) at the time of biopsy. The objective of this study was to acquire and analyze spectral data and correlative tissue biopsy cores using the ClariCore Optical Biopsy System (COBS) for training and development of a prostate tissue classification algorithm.
METHODS: COBS is comprised of a 16-gauge core biopsy needle with an integrated optical sensor and a console which provides real-time prostate tissue classification information prior to tissue collection. Auto advancing of the inner needle via a built-in motor allows tissue classification along the length of the core in 1 mm increments. Men, scheduled for TRUS-guided biopsy with a prostate volume > 20cc were included in this multicenter study. Using COBS, 10-12 tissue biopsy cores were targeted from each patient. Fluorescence spectra at 280 and 340 nm excitations and elastic scattering spectra between 400-750 nm were collected for every core in 1 mm steps. For each tissue core, 1 mm segments were histopathologically classified either as benign or malignant and correlated with respective spectra measurements. RESULTS: Of the 144 patients included in the intent to treat analysis, 142 (98.6%) had biopsy cores successfully collected with the COBS. In total, 1,158 biopsy cores collected with the COBS were used for algorithm development. Of these cores, 185 (16.0%) were found to contain PCa. The COBS algorithm results are provided in Table 1 . During the course of the study no serious adverse events were reported.
CONCLUSIONS: This study demonstrated that COBS can successfully acquire spectral data and correlative tissue biopsy cores for algorithm development. High sensitivity and negative predictive value can be used for precise targeting of PCa lesions with subsequent improvement in the diagnostic yield of TRUS-guided prostate biopsies. The COBS procedure was safe and well-tolerated by patients. Additional studies are underway to further establish accuracy and clinical utility.
Source of Funding: Precision Biopsy Inc., Aurora, CO
MP13-07 NEXT-GENERATION LIQUID BIOPSIES USING EXTRACELLULAR VESICLE DETECTION BY NANOSCALE FLOW CYTOMETRY
Fabrice Lucien-Matteoni*, Rochester, MN; Janice Gomes, Harmenjit Brar, London, Canada; Matthew Lowerison, Mario Cepeda, Vidhu Joshi, Yohan Kim, Paras Shah, Rochester, MN; Stephen Pautler, Nicholas Power, London, Canada; Haidong Dong, Stephen Boorjian, Bradley Leibovich, Rochester, MN INTRODUCTION AND OBJECTIVES: Next-generation biomarkers are emerging as valuable tools to improve cancer diagnostics, disease stratification and treatment monitoring. Our group has developed an innovative "liquid biopsy" based on enumeration of submicron cell fragments called extracellular vesicles (EVs) that bear tissue and cancer-specific biomarkers. This approach relies on the use of nanoscale flow cytometry (nFC) allowing high-throughput multiparametric detection and enumeration of particles of events between 100-1000 nm in diameter. Despite the growing interest for developing EV-based blood tests, there is still an unmet need to optimize preanalytical procedures and analytical parameters.
Our team has established the standard operating procedures required for accurate detection of EVs from patient plasmas.
METHODS: We utilized the A50-Micro Plus nanoscale flow cytometer (Apogee FlowSystems Inc.) to identify and measure 100-1000nm sized EVs. Silica and polystyrene beads were used to determine resolution limits of the nFC and established optimal acquisition parameters for EV enumeration. Plasmas from healthy volunteers and cancer patients were used to standardize preanalytical conditions (plasma isolation, storage, handling) and to assess the performance of the nFC.
RESULTS: A50-Micro Plus was capable of detecting EVs from 110 to 1000 nm in a linear manner by using light-scatter and fluorescence detection. Platelet-free plasma, storage temperature (-80C), dilution range (1/15-1/60) are critical considerations to ensure integrity and accurate enumeration of EVs. We used the standard operating procedure to enumerate prostate cancer-derived EVs in prostate cancer patients and unveiled a blood signature which identifies patients with clinically significant prostate cancers.
CONCLUSIONS: We have established a workflow to develop EV-based liquid biopsies using nanoscale flow cytometry. In prostate cancer, we have identified an EV signature that may enhance selective identification of patients with clinically significant prostate cancer and decrease unnecessary tissue biopsies in individuals with absent or low-risk disease. This technique has the potential to facilitate the development of next-generation peripheral blood tests to allow personalized treatment protocols for patients with urogenital cancers.
Source of Funding: Movember Foundation, Mayo Clinic
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